Immunic, Inc.
NASDAQ:IMUXBiotechnology
Healthcare
$7.39 -0.28%
-$0.04 today
- Market cap
- $100.83M
- Beta
- 1.39
- P/E (TTM)
- -4.1
- EPS (TTM)
- -$3.46
52W Low $5.06High $15.77
Volume 0.39M
Average 0.27M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$85.81M
FY 2025 · Annual
Investing Cash Flow
-$161,000.00
FY 2025 · Annual
Financing Cash Flow
$65.58M
FY 2025 · Annual
-12.0% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (92.95M) | (120.41M) | (93.61M) | (100.51M) | (97.17M) |
| Depreciation & Amortization | 85K | 77K | 111K | 134K | 168K |
| Deferred Income Tax | 4.33M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 5.95M | 7.93M | 7.1M | 8.53M | 8.86M |
| Change in Working Capital | (9.28M) | 9.53M | 15.05M | 564K | 1.84M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 176K | 799K | 817K | 3.15M | 1.24M |
| Other Working Capital | (9.46M) | 8.73M | 14.23M | (2.58M) | 601K |
| Other Non-Cash Items | 8.63M | 37.73M | 523K | 6.52M | 497K |
| Operating Cash Flow | (83.23M) | (65.14M) | (70.83M) | (84.77M) | (85.81M) |
| Capital Expenditures | (67K) | (112K) | (334K) | (264K) | (161K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (9.63M) | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 9.8M | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (67K) | (9.74M) | 9.46M | (264K) | (161K) |
| Debt Repayment | 0 | 0 | 0 | 74.27M | 0 |
| Common Stock Issued | 42.75M | 39.58M | 853K | 191K | 65.58M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 92K | 187K | 180K | 77K | 0 |
| Financing Cash Flow | 42.84M | 95.76M | 1.03M | 74.54M | 65.58M |
| Effect of Forex Changes | (130K) | (993K) | 262K | (517K) | 205K |
| Net Change in Cash | (40.59M) | 19.88M | (60.07M) | (11.01M) | (20.19M) |
| Free Cash Flow | (83.3M) | (65.26M) | (71.16M) | (85.03M) | (85.97M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$97.2M
+ D&A$168.0K
+ Stock-Based Comp$8.9M
+ Deferred Tax$0
+ Working Capital$1.8M
+ Other Non-Cash$497.0K
= Operating Cash Flow-$85.8M
- Capex-$161.0K
= Free Cash Flow-$86.0M
Analysis
FY2025 free cash flow is -$86.0M. FCF conversion is 88.5% of net income. Operating cash flow was -$85.8M, with capex of -$161.0K. The largest bridge item is Stock-Based Comp at $8.9M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G | SC 13G filing | Nov 13, 2026 | |
| 10-Q | Quarterly report | Nov 13, 2026 | |
| 8-K | Current report | Nov 13, 2026 | |
| 8-K | Current report | Nov 5, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 2, 2026 |
Does IMUX generate free cash flow?
Immunic, Inc. (IMUX) generated -$85.97M of free cash flow in fiscal 2025.
How much operating cash flow does IMUX produce?
Operating cash flow was -$85.81M, before capital expenditures of $161,000.00.
Continue the stock analysis
Jump to another research area for this company.